Genetic Toxicology Journals
Genetic toxicologyv studies are conducted to assess the potential for induction of genetic
mutations or chromosomal damage. Genetic toxicity testing is required for all classes of chemicals and drugs, but its conduct can differ from compound to compound to account for regulatory requirements and choice and design of assays. For more than 30 years, Charles River has been helping clients to develop custom testing strategies and conduct appropriate assays to meet the unique requirements of their chemicals and drugs. With three sites in North America and Europe, our team includes more than 70 scientists and staff who are dedicated to the field of genetic toxicology, as well as regulatory consultants and program managers who can support our clients’ studies with strategic advice. Our ongoing involvement with regulatory working groups (e.g., OECD Expert Working Groups) and international societies (e.g., Genetic
Toxicology Association) ensures that our clients have access to the latest developments in science and its and applications in the regulatory environment. Determination of a compound’s potential
genotoxicity is an important component of a complete safety assessment of nearly all new products (e.g., pharmaceutical ingredients, pharmaceutical impurities, unique human metabolites, industrial chemicals, agrochemicals, cosmetics). Performed early on, it can help to determine whether further development is appropriate and what, if any, additional testing is needed to investigate and characterize the relevance of any observed adverse effects. While most studies are performed in vitro, we also incorporate in vivo genetic
toxicology studies when necessary.
High Impact List of Articles
-
Ex situ online monitoring: application, challenges and opportunities for biopharmaceuticals processes
Paul Kroll, Patrick Sagmeister, Wieland Reichelt, Lukas Neutsch, Tobias Klein & Christoph Herwig*
Review Article: Pharmaceutical Bioprocessing
-
Ex situ online monitoring: application, challenges and opportunities for biopharmaceuticals processes
Paul Kroll, Patrick Sagmeister, Wieland Reichelt, Lukas Neutsch, Tobias Klein & Christoph Herwig*
Review Article: Pharmaceutical Bioprocessing
-
Improving sialylation of recombinant biologics for enhanced therapeutic efficacy
Kah Fai Chan, John SY Goh and Zhiwei Song
Editorial: Pharmaceutical Bioprocessing
-
Improving sialylation of recombinant biologics for enhanced therapeutic efficacy
Kah Fai Chan, John SY Goh and Zhiwei Song
Editorial: Pharmaceutical Bioprocessing
-
Next-generation sequencing technologies and their potential impact on CHO cell-based biomanufacturing
Benjamin Kremkow and Kelvin H Lee
Review Article: Pharmaceutical Bioprocessing
-
Next-generation sequencing technologies and their potential impact on CHO cell-based biomanufacturing
Benjamin Kremkow and Kelvin H Lee
Review Article: Pharmaceutical Bioprocessing
-
Cell culture processes for biologics manufacturing: recent developments and trends
Shang-Tian Yang, Xiaoguang Liu
Editorial: Pharmaceutical Bioprocessing
-
Cell culture processes for biologics manufacturing: recent developments and trends
Shang-Tian Yang, Xiaoguang Liu
Editorial: Pharmaceutical Bioprocessing
-
Considerations in upstream bioprocess
monitoring and statistical data analysis
in the
context of process analytical technology and
quality by design
Gerald Striedner & Karl Bayer
Review Article: Pharmaceutical Bioprocessing
-
Considerations in upstream bioprocess
monitoring and statistical data analysis
in the
context of process analytical technology and
quality by design
Gerald Striedner & Karl Bayer
Review Article: Pharmaceutical Bioprocessing
Relevant Topics in Clinical